HISTONE MODIFICATIONS GUIDING HIV INTEGRATION
指导 HIV 整合的组蛋白修饰
基本信息
- 批准号:10619868
- 负责人:
- 金额:$ 19.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-11 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAffinity ChromatographyAnti-Retroviral AgentsBindingBinding ProteinsBioinformaticsC-terminalCellsChIP-seqChromatinComplexDataDatabasesDiseaseElementsEncyclopedia of DNA ElementsEnsureEventFluorescenceFluorescence MicroscopyFluorescence Resonance Energy TransferGene ExpressionGenesGenetic TranscriptionGenomeGenomicsGoalsHIVHistone H3HistonesIn VitroIndividualInfectionIntegraseIntercistronic RegionKineticsLocationLysineMagnetismMapsMass Spectrum AnalysisMediatingMethylationModalityN-terminalNucleosomesPWWP DomainPatientsPersonsPost-Translational Protein ProcessingProcessProductionProteinsProvirus IntegrationProvirusesRecombinantsRoleSiteTechnologyTherapeuticTimeTranscription CoactivatorTranscription Initiation SiteViralViral GenomeVirusVirus DiseasesVirus Integrationantiretroviral therapycell typecellular engineeringcofactorhistone methylationhistone modificationin vivointegration sitenovelpreferencesingle moleculetherapeutic targettranscriptional coactivator p75viral DNA
项目摘要
HISTONE MODIFICATIONS GUIDING HIV INTEGRATION
PROJECT SUMMARY / ABSTRACT
Human immunodeficiency virus (HIV-1) is the causative agent of acquired immunodeficiency syndrome (AIDS)
with ~36.7 million people currently infected worldwide. Integration of the viral genome establishes an irreversible
insertion of the proviral sequence into the host chromatin. The integrated genome ensures effective HIV gene
expression and ultimately virus production or the establishment of latency where the provirus remains dormant
for an extended time. Retroviral integration is mediated by the viral integrase (IN) protein that is bound to the
direct-repeated ends of the viral DNA genome, along with additional cellular and viral co-factors that direct
integration to host chromatin sites. The overarching goal of this proposal is to understand how viral integration
is targeted to chromatin by histone post translational modifications (PTMs), and how cellular factors that tightly
control the localization of these PTMs influence target site choice.
LEDGF/p75 is a key cellular transcription co-activator that binds to HIV-1 IN via a C-terminal integrase binding
domain (IBD). The N-terminus of LEDGF/p75 contains a PWWP domain that is expected to recognize histone
methylated lysine PTMs. Bimodal tethering of the HIV-1 integration complex (intasome) to a transcription-related
histone PTM has been proposed to account for the observed ~76% of chromosomal integrations that occur in
actively transcribed genes. LEDGF/p75 purportedly targets HIV-1 to nucleosomes containing trimethylation of
histone H3 lysine 36 residues (H3K36me3). However, H3K36me3 is most often found at the 3’ ends of
transcribed genes, whereas HIV-1 integrates more frequently toward the 5’ ends of genes.
Bioinformatic correlations of HIV-1 integration sites with histone PTMs is limited by the data available in the
Encyclopedia of DNA Elements (ENCODE) database. Notably absent from ENCODE are genomic maps of the
H3K36me2 PTM in any cell type. We performed a ChIP-Seq analysis of H3K36me2 and determined that it was
commonly found near the 5’ transcription start site of genes. Moreover, we found that HIV-1 integration sites
correlate better with the location of H3K36me2 than H3K36me3. We propose to examine the role of H3K36me2
and H3K36me3 with two Specific Aims. Aim 1 will expand the current understanding of H3K36 methylation and
its connection to HIV-1 integration efficiency and site selection in vivo. Aim 2 will probe the influence of
H3K36me2 and H3K36me3 on HIV-1 integration in vitro. Our approaches will include technologically advanced
mass spectrometry, integration site mapping, and single molecule fluorescence microscopy. The results of these
studies will clearly determine the role of H3K36me2 and H3K36me3 during HIV-1 integration.
指导HIV整合的组蛋白修饰
项目总结/摘要
人类免疫缺陷病毒(HIV-1)是获得性免疫缺陷综合征(AIDS)的病原体
目前全球约有3670万人感染。病毒基因组的整合建立了一个不可逆的
前病毒序列插入宿主染色质。整合的基因组确保有效的HIV基因
表达并最终产生病毒或建立潜伏期,其中前病毒保持休眠
很长一段时间逆转录病毒整合由病毒整合酶(IN)蛋白介导,所述病毒整合酶(IN)蛋白结合至逆转录病毒载体。
病毒DNA基因组的直接重复末端,沿着另外的细胞和病毒辅因子,
整合到宿主染色质位点。这项提案的首要目标是了解病毒整合是如何
通过组蛋白翻译后修饰(PTM)靶向染色质,以及细胞因子如何紧密地
控制这些PTM的定位影响靶位点的选择。
LEDGF/p75是通过C-末端整合酶结合与HIV-1 IN结合的关键细胞转录共激活因子
结构域(IBD)。LEDGF/p75的N-末端含有预期识别组蛋白的PWWP结构域
甲基化赖氨酸PTM。HIV-1整合复合物(整合体)与转录相关蛋白的双峰连接
已经提出组蛋白PTM解释了观察到的约76%的染色体整合,这些染色体整合发生在
活跃转录的基因LEDGF/p75据称将HIV-1靶向含有三甲基化的
组蛋白H3赖氨酸36个残基(H3 K36 me 3)。然而,H3 K36 me 3最常出现在3'末端
转录基因,而HIV-1整合更频繁地向5'端的基因。
HIV-1整合位点与组蛋白PTM的生物信息学相关性受到文献中可用数据的限制。
Encyclopedia of DNA Elements(ENCODE)数据库。值得注意的是,ENCODE中缺少
任何细胞类型中的H3 K36 me 2 PTM。我们对H3 K36 me 2进行了ChIP-Seq分析,并确定它是
通常在基因的5'转录起始位点附近发现。此外,我们发现HIV-1整合位点
与H3 K36 me 3相比,与H3 K36 me 2的位置相关性更好。我们建议研究H3 K36 me 2的作用
和H3 K36 me 3,具有两个特定目的。目的1将扩大目前对H3 K36甲基化的理解,
其与HIV-1整合效率和体内位点选择的关系。目标2将探讨
H3 K36 me 2和H3 K36 me 3对HIV-1体外整合的影响。我们的方法将包括技术先进的
质谱、整合位点作图和单分子荧光显微术。的结果予以
研究将清楚地确定H3 K36 me 2和H3 K36 me 3在HIV-1整合过程中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ross C. Larue其他文献
Interaction of the HIV-1 intasome with Transportin 3 ( TNPO 3 or TRN-SR 2 )
HIV-1 嵌体与转运蛋白 3(TNPO 3 或 TRN-SR 2)的相互作用
- DOI:
- 发表时间:
2012 - 期刊:
- 影响因子:0
- 作者:
Ross C. Larue;Kushol Gupta;C. Wuensch;Nikoloz Shkriabai;J. Kessl;Eric M. Danhart;Lei Feng;O. Taltynov;F. Christ;G. Duyne;Z. Debyser;M. Foster;M. Kvaratskhelia - 通讯作者:
M. Kvaratskhelia
Ribosomal intergenic spacer- and DGGE- based analyses of microbial consortia associated with liquid and particulate fractions of rumen digesta
基于核糖体基因间间隔区和 DGGE 的与瘤胃食糜液体和颗粒部分相关的微生物群落分析
- DOI:
- 发表时间:
2001 - 期刊:
- 影响因子:0
- 作者:
Ross C. Larue - 通讯作者:
Ross C. Larue
Ross C. Larue的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10506915 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
- 批准号:
1746198 - 财政年份:2018
- 资助金额:
$ 19.69万 - 项目类别:
Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
- 批准号:
512537-2017 - 财政年份:2017
- 资助金额:
$ 19.69万 - 项目类别:
University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
- 批准号:
1404605 - 财政年份:2014
- 资助金额:
$ 19.69万 - 项目类别:
Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
- 批准号:
1263713 - 财政年份:2013
- 资助金额:
$ 19.69万 - 项目类别:
Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
- 批准号:
425749-2012 - 财政年份:2012
- 资助金额:
$ 19.69万 - 项目类别:
Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
- 批准号:
1159886 - 财政年份:2012
- 资助金额:
$ 19.69万 - 项目类别:
Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
- 批准号:
19560760 - 财政年份:2007
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
- 批准号:
234753-2000 - 财政年份:2003
- 资助金额:
$ 19.69万 - 项目类别:
Collaborative Research and Development Grants